Cancer & Signaling Discussion Group
The genetic and epigenetic alterations that evolve during tumorigenesis ultimately conspire to perturb the complex systems of molecular signalling pathways. By understanding how pathways are regulated normally, and how they are dysregulated in cancer, scientists hope to identify molecular targets that will be receptive to therapeutic intervention.
The Cancer & Signaling Discussion Group provides a forum for exploring the molecular networks that play a role in cancer predisposition, initiation, and progression. The group also focuses on the responses of tumors to therapeutic intervention, including through feedback loops, acquired alterations, and interaction with the microenvironment. Meetings of the group focus on specific themes related to signal transduction dysregulation in oncogenesis, and cover basic, translational, clinical, and diagnostic aspects of the field.
Friday, October 12, 2012 | 12:00 PM - 4:00 PM
Organizers: Kenneth P. Olive (Columbia University Medical Center), George Zavoico (MLV), Jennifer Henry (The New York Academy of Sciences)
Keynote Speaker: Dafna Bar-Sagi (NYU Langone Medical Center)
Speakers: Adrienne D. Cox (University of North Carolina at Chapel Hill), Jeffrey M. Hardacre (University Hospitals Case Medical Center), Alec Kimmelman (Dana Farber Cancer Institute), David Tuveson (Cold Spring Harbor Laboratory)
Breakthroughs in pancreatic ductal adenocarcinoma have led to novel therapies. This symposium covers the latest research developments in pancreatic cancer, with a focus on preclinical and early clinical investigations of rationally targeted drugs.
Tuesday, May 1, 2012 | 1:00 PM - 5:00 PM
Organizers: Kenneth P. Olive (Columbia University Medical Center), Philip Thorpe (UT Southwestern Medical Center), George Zavoico (MLV), and Jennifer Henry (The New York Academy of Sciences)
Speakers: Ari Helenius (ETH Hönggerberg), Philip Thorpe (UT Southwestern Medical Center), Chris Reutlingsperger (University of Maastricht), Alan Schroit (UT Southwestern Medical Center), and David Ucker (University of Illinois at Chicago)
This symposium will highlight recent developments in the understanding of PS exposure, its biological consequences, and its exploitation to create novel agents for the detection and treatment of cancer and viral diseases.
Wednesday, March 14, 2012 | 1:00 PM - 5:00 PM
Organizers: Ken Olive (Columbia University Medical Center), Barry Selick (Threshold Pharmaceuticals), George Zavoico (MLV), Jennifer Henry (The New York Academy of Sciences)
Speakers: Charles P. Hart (Threshold Pharmaceuticals), Giovanni Melillo (Bristol-Myers Squibb), Maria V. Papadopoulou (NorthShore University HealthSystem, University of Chicago), Mark Dewhirst (Duke University Medical Center), Hartmuth Kolb (Siemens Healthcare USA)
The altered chemical environment of hypoxic regions provides a mechanistic basis for the development of novel cancer therapies and imaging agents. This symposium will explore advances in the development of tumor-specific drugs targeting hypoxia.
Thursday, February 10, 2011 | 1:00 PM - 5:00 PM
Speakers: Michael B. Sporn (Dartmouth Medical School), Elizabeth A. Grimm (MD Anderson Cancer Center), Dmitry Gabrilovich (H. Lee Moffitt Cancer Center), Colin Meyer (Reata Pharmaceuticals, Inc.) and Stephen T. Sonis (Harvard/Farber Cancer Center)
Reactive oxygen and nitrogen species (RONS) are implicated in cancer and inflammation pathogenesis. This symposium covers the mechanisms that regulate their generation and metabolism, their role in disease, and the development of novel therapeutics. Presented as part of the Translational Medicine Initiative.
Tuesday, November 16, 2010 | 1:00 PM - 5:00 PM
Speakers: Greg Hannon (Cold Spring Harbor Laboratory), Pier Paolo Pandolfi (Harvard Medical School), John Rinn (Harvard Medical School), Ramin Shiekhattar (The Wistar Institute), David Spector (Cold Spring Harbor Laboratory)
Non- coding RNAs are emerging as important regulators of development and function in many physiological processes. Their role in controlling pathogenesis and their potential as targets for therapeutic intervention are becoming increasingly apparent. Presented as part of the Translational Medicine Initiative.
Wednesday, May 12, 2010 | 9:00 AM - 6:00 PM
Speakers: Andrea Califano (Columbia University Medical Center), James R. Downing (St. Jude Children's Research Hospital), Joe W. Gray (Lawrence Berkeley National Laboratory/UCSF), Antonio Iavarone (Columbia University Medical Center), Douglas A. Lauffenburger (Massachusetts Institute of Technology), Arnold J. Levine (Institute for Advanced Study/CINJ at UMDNJ-RWJMS), Leona D. Samson (Massachusetts Institute of Technology), Chris Sander (Memorial Sloan-Kettering Cancer Center), and Marc Vidal (Dana Farber Cancer Institute/Harvard Medical School)
This meeting brings together researchers using systems biology to interrogate the networks underlying multiple cancers, model their perturbations, and identify novel candidate targets for diagnostic and therapeutic intervention.
Wednesday, March 17, 2010 | 1:00 PM - 5:00 PM
Speakers: Julian Adams (Infinity Pharmaceuticals Inc.), Andy McMahon (Harvard University), Kenneth Olive (Columbia University), Robert Yauch (Genentech, Inc.)
The Hedgehog Signaling Pathway regulates processes essential for embryo development, offering a novel approach to the treatment of some cancers. This meeting reviews its role in disease pathogenesis and discusses potential therapeutic opportunities.
Wednesday, May 10, 2006 | 1:00 PM - 1:00 PM
We are proud to announce the premiere event of the Cancer and Signaling Discussion Group. This group is the most recent addition to the Frontiers of Science Program
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
Harvard Medical School
Mission Partner support for the Frontiers of Science program provided by
Get more information about how you can sponsor a discussion group.